Reference number : GC-2017-Q2-00040, amendment number : , agreement type : G, recipient legal name : Schriemer, David (University of Calgary), recipient country : CA, recipient province : nan, recipient city : Alberta, recipient postal code : nan, program name english : Idea to Innovation, program name french : De l'idée à l'innovation, program purpose english : Imagine spending hundreds of thousands of dollars on powerful new technology for life science research, only_x000D_
to discover that you cannot fully use the data that it produces. This is a situation in a large number of academic_x000D_
and industry laboratories that have purchased mass spectrometers for R&D spanning all areas of biological and_x000D_
environmental sciences. New technologies in mass spectrometry have spurred tremendous growth in new_x000D_
methods for compound characterization, especially in the biopharmaceuticals industry. Biopharmaceuticals are_x000D_
protein drugs. They represent a very effective class of pharmaceutical agents and the area is experiencing a_x000D_
high rate of growth worldwide. Mass spectrometry is the perfect choice of technology to support the_x000D_
development of new protein drugs, and to ensure that these complicated drugs are safe to use. The companies_x000D_
that make mass spectrometers are not able to keep up with the many new directions that biopharmaceutical_x000D_
companies are taking mass spectrometry, and the situation is expected to deteriorate further. We developed a_x000D_
transformative solution to this problem, in the form of an application-building software platform called the_x000D_
Mass Spec Studio. This platform strongly reduces the development time for creating new applications. It is_x000D_
currently houses research-grade plug-ins that are very useful for a form of protein characterization called_x000D_
higher-order structure (HOS) analysis. In this project we will complete version 2 of the Mass Spec Studio. It_x000D_
will contain industry-leading plug-ins for HOS analysis and streamline the application development process_x000D_
even further. The goal of the project is to create a package of technologies that will help mass spectrometry_x000D_
keep pace with the needs of the biopharmaceutical industry, and ensure that protein drugs are effective and_x000D_
safe., program purpose french : Imagine spending hundreds of thousands of dollars on powerful new technology for life science research, only_x000D_
to discover that you cannot fully use the data that it produces. This is a situation in a large number of academic_x000D_
and industry laboratories that have purchased mass spectrometers for R&D spanning all areas of biological and_x000D_
environmental sciences. New technologies in mass spectrometry have spurred tremendous growth in new_x000D_
methods for compound characterization, especially in the biopharmaceuticals industry. Biopharmaceuticals are_x000D_
protein drugs. They represent a very effective class of pharmaceutical agents and the area is experiencing a_x000D_
high rate of growth worldwide. Mass spectrometry is the perfect choice of technology to support the_x000D_
development of new protein drugs, and to ensure that these complicated drugs are safe to use. The companies_x000D_
that make mass spectrometers are not able to keep up with the many new directions that biopharmaceutical_x000D_
companies are taking mass spectrometry, and the situation is expected to deteriorate further. We developed a_x000D_
transformative solution to this problem, in the form of an application-building software platform called the_x000D_
Mass Spec Studio. This platform strongly reduces the development time for creating new applications. It is_x000D_
currently houses research-grade plug-ins that are very useful for a form of protein characterization called_x000D_
higher-order structure (HOS) analysis. In this project we will complete version 2 of the Mass Spec Studio. It_x000D_
will contain industry-leading plug-ins for HOS analysis and streamline the application development process_x000D_
even further. The goal of the project is to create a package of technologies that will help mass spectrometry_x000D_
keep pace with the needs of the biopharmaceutical industry, and ensure that protein drugs are effective and_x000D_
safe., agreement title english : Mass spec studio software for the pharmaceutical market - a phase one project, agreement title french : Mass spec studio software for the pharmaceutical market - a phase one project, agreement number : I2IPJ, agreement value : 125000.0, agreement start date : 2017-07-12, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada